Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

18 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Maxaquin Articles

Unimed Acquires US Rights To Searle's Maxaquin

24 February 1997

Mixed Six Month Results From Japan's Drugmakers

9 January 1995

FDA PANEL BACKS ROCHE'S MEGALONE

28 March 1994

FLUOROQUINOLONES - SEIZURE RATES

11 October 1993

SEARLE HALTS MAXAQUIN COPROMOTION

9 August 1993

AMERICAN HOME HAS CONFIDENCE FOR 1993

12 April 1993

ROBERTS ACQUIRES SEARLE PRODUCTS

5 April 1993

SEARLE MEDICINES DONATION

1 February 1993

FDA APPROVES 26 NEWDRUGS IN 1992

25 January 1993

GOOD GROWTH FOR US COMPANIESCONTINUES FOR US COs

3 August 1992

SEARLE'S MAXAQUIN

29 June 1992

SALES RISE BUT PROFITS POOR FOR FIRMS IN JAPAN

29 June 1992

Maxaquin to be copromoted

8 June 1992

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • AstraZeneca plans to move three cancer drug candidates into Ph III
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • AstraZeneca plans to move three cancer drug candidates into Ph III
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS